# A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors

> **NCT05346484** · PHASE1 · TERMINATED · sponsor: **Imugene Limited** · enrollment: 66 (actual)

## Conditions studied

- Solid Tumor
- Solid Carcinoma
- Solid Tumor, Adult
- Metastatic Cancer
- Advanced Solid Tumor
- Cholangiocarcinoma
- Bile Duct Cancer

## Interventions

- **BIOLOGICAL:** CF33-hNIS
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Modified FOLFOX

## Key facts

- **NCT ID:** NCT05346484
- **Lead sponsor:** Imugene Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-17
- **Primary completion:** 2026-01-12
- **Final completion:** 2026-01-12
- **Target enrollment:** 66 (ACTUAL)
- **Why stopped:** Portfolio prioritization
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05346484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05346484, "A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05346484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*